Breaking News Instant updates and real-time market news.

AAPL

Apple

$207.56

-0.66 (-0.32%)

, DDAIF

Daimler AG

$0.00

(0.00%)

10:28
08/11/18
08/11
10:28
08/11/18
10:28

Week in review: How Trump's policies moved stocks

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap compiled by The Fly: 1. CHINA TARIFFS: The Trump administration finished plans to implement new tariffs on $16B of Chinese imports to punish Beijing for its trading practices, bringing the total value of products covered by the levies to $50B by the end of the month, the U.S. Trade Representative's office announced. The office made slight adjustments to an original list of products it was considering, removing five items and leaving 279 products, mainly chemicals and electronic parts still subject to the tax and China has already announced plans to retaliate with tariffs of an equivalent amount on U.S. goods. 2. APPLE COULD BE 'BARGAINING CHIP': Apple (AAPL), which has leveraged cheap labor and a good supply chain in China, could be used as a "bargaining chip" in the U.S.-China trade war, according to CNBC, citing an article in the state-backed People's Daily in China. Apple made $9.6B in China in this past quarter, but could be the mark of "nationalist sentiment" if the trade war hits Chinese companies hard. 3. IRAN SANCTIONS: On Thursday, President Trump tweeted, "The Iran sanctions have officially been cast. These are the most biting sanctions ever imposed, and in November they ratchet up to yet another level. Anyone doing business with Iran will NOT be doing business with the United States. I am asking for WORLD PEACE, nothing less!" Amid renewed U.S. sanctions, Daimler (DDAIF) has discarded its plans to expand its Iran business, according to Reuters, citing a company statement. Daimler said its actions in Iran were already restricted before ceasing them in accordance to sanctions. In 2016, Daimler established a joint venture in Iran to make and sell Mercedes-Benz trucks and also had plans to open a representative office in Teheran. 4. TURKEY SANCTION: On Friday, President Trump tweeted, "I have just authorized a doubling of Tariffs on Steel and Aluminum with respect to Turkey as their currency, the Turkish Lira, slides rapidly downward against our very strong Dollar! Aluminum will now be 20% and Steel 50%. Our relations with Turkey are not good at this time!" Publicly traded stocks in the metals space include US Steel (X), AK Steel (AKS), Nucor (NUE), Steel Dynamics (STLD), Alcoa (AA), Century Aluminum (CENX), and Cleveland-Cliffs (CLF). 5. MEDICARE ADVANTAGE PLANS: On Tuesday, the Centers for Medicare and Medicaid Services gave new authority to Medicare Advantage plans that allows those plans to negotiate lower drug prices. The policy will also allow Medicare Advantage plans to cross-manage across Part B and Part D as applicable. Publicly traded drugmakers that analysts identified as likely to be impacted by the news include Regeneron (REGN), Amgen (AMGN), Roche (RHHBY) and Johnson & Johnson (JNJ). 6. SPACE FORCE: President Donald Trump will call on Congress to allocate $8B over the next five years to create the U.S. Space Force. This will become the sixth branch of the military, an idea that has faced resistance from the Air Force, which currently oversees military space programs, Bloomberg has noted. The U.S. already has a space-based military footprint, with the sky teeming with spy satellites and other platforms that support government surveillance and communications, and with the Air Force also owning a top-secret aircraft built by Boeing (BA), Bloomberg has said. "Week in Review" is The Fly's weekly recap of its recurring series of "Trump Effect" exclusive stories.

AAPL

Apple

$207.56

-0.66 (-0.32%)

DDAIF

Daimler AG

$0.00

(0.00%)

X

U.S. Steel

$29.96

-0.29 (-0.96%)

AKS

AK Steel

$4.31

-0.06 (-1.37%)

NUE

Nucor

$63.48

0.07 (0.11%)

STLD

Steel Dynamics

$43.54

-0.77 (-1.74%)

AA

Alcoa

$45.01

1.99 (4.63%)

CENX

Century Aluminum

$12.15

0.01 (0.08%)

CLF

Cleveland-Cliffs

$10.32

0.09 (0.88%)

REGN

Regeneron

$368.77

-3.55 (-0.95%)

AMGN

Amgen

$194.43

0.5 (0.26%)

RHHBY

Roche

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.75

-0.45 (-0.34%)

BA

Boeing

$339.42

-4.3 (-1.25%)

  • 11

    Aug

  • 14

    Aug

  • 25

    Aug

  • 11

    Sep

  • 20

    Oct

  • 28

    Oct

  • 09

    Nov

AAPL Apple
$207.56

-0.66 (-0.32%)

08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
08/02/18
SBSH
08/02/18
NO CHANGE
Target $5
SBSH
Sell
Citi reiterates Sell on Fitbit, says not an acquisition target
Citi analyst Jim Suva reiterates a Sell rating on Fitbit (FIT) with a $5 price target following the company's Q2 results, which he notes were largely better than expected except for a decline in free cash flow. Apple's (AAPL) smart watch is smarter than Fitbit's (FIT) smartwatches, which do not allow "robust" two-way communication or a lengthy app catalog, and the price differential is immaterial, Suva tells investors in a post-earnings research note. Further, he does not see Fitbit as an acquisition target.
08/01/18
BTIG
08/01/18
NO CHANGE
Target $235
BTIG
Buy
Apple price target raised to $235 from $207 at BTIG
BTIG analyst Walter Piecyk, in a note published last night, raised his price target on Apple (AAPL) shares to $235 from $207, stating that he believes there are early signs that upgrade rates might be bottoming and noting that iPhone revenue grew by over 20% despite "historic low" upgrade rates in Q3. Apple CEO Tim Cook hinted at a noteworthy content project, added Piecyk, who agrees with fellow BTIG analyst Rich Greenfield's view that Apple is likely to follow Netflix (NFLX) and Amazon's (AMZN) approach "build their way into the market rather than buy their way in" to video. Piecyk keeps a Buy rating on Apple shares.
08/09/18
JPMS
08/09/18
NO CHANGE
JPMS
Neutral
Lumentum selloff provides attractive entry point, says JPMorgan
JPMorgan analyst Samik Chatterjee believes the post-earnings pullback in shares of Lumentum (LITE) provides an attractive entry point. However, he keeps a Neutral rating on Lumentum with an $80 price target. The shares sold off yesterday as management chose to provide conservative 3D Sensing revenue guidance for fiscal Q2 ahead of greater visibility into market share development and inventory position with its primary customer, Apple (AAPL), on next generation phones expected to be launched in September, Chatterjee tells investors in a research note. Based on his conversations with management, Chatterjee believes the softer guide is driven entirely by a lower market share assumption and budgeting for inventory timing "purely out of conservatism." This increases the likelihood of an upside surprise, the analyst contends.
DDAIF Daimler AG
$0.00

(0.00%)

07/05/18
07/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Fiat Chrysler (FCAU) upgraded to Buy from Hold and Daimler AG (DDAIF) upgraded to Hold from Underperform at Jefferies with analyst Philippe Houchois citing valuation. 2. Danone (DANOY) upgraded to Outperform from Sector Perform at RBC Capital with analyst James Jones saying he now has less "punitive" assumptions about the company's sales growth and capital expenditures as its profits have become less reliant on dairy. 3. Hexcel (HXL) upgraded to Buy from Hold at Canaccord with analyst Ken Herbert stating he believes the acceleration in growth expected in 2018 will continue into 2019. 4. Qorvo (QRVO) upgraded to Overweight from Sector Weight at KeyBanc with analyst Michael McConnell citing healthy China smartphone trends, stabilizing Apple (AAPL) iPhone demand, and greater than expected market share gains in China smartphones. 5. Advanced Energy (AEIS) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying the company's 9% free cash flow yield has turned the shares into an appealing deep value story, despite slowing organic growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/18
MZHO
07/05/18
NO CHANGE
MZHO
June Class 8 truck orders rose 'astounding' 133% year-over-year, says Mizuho
June Class 8 truck orders didn't just beat estimates, the actual number "made everyone look silly," Mizuho analyst Kristine Kubacki tells investors in a research note. Class 8 orders surged to 42,200 units in June, up an "astonishing" 133% year-over-year, Kubacki writes. The number handily beat the 30,000 mid-point of her estimate. Publicly traded truck makers and suppliers include Daimler AG (DDAIF), Paccar (PCAR), CNH Industrial (CNHI), Navistar (NAV), Cummins (CMI) and Allison Transmission (ALSN). :theflyo
07/05/18
JEFF
07/05/18
UPGRADE
Target $23
JEFF
Buy
Jefferies upgrades Fiat Chrysler to Buy on valuation
Jefferies analyst Philippe Houchois upgraded Fiat Chrysler (FCAU) to Buy from Hold while lowering his price target for the shares to $23 from $26. The analyst this morning also upgraded Daimler AG (DDAIF) to Hold from Underperform. The analyst cites valuation for both upgrades. The recent selloff in Fiat Chrysler looks "severe" given the likelihood of increasing margins, the 24% free cash flow yield, and the potential for corporate change, Houchois tells investors in a research note.
07/05/18
JEFF
07/05/18
UPGRADE
JEFF
Hold
Daimler AG upgraded to Hold from Underperform at Jefferies
Jefferies analyst Philippe Houchois upgraded Daimler AG to Hold while lowering his price target for the shares to EUR 58 from EUR 60. The analyst believes the shares at current levels are already pricing in concerns about lower margins versus peers, risks to the dividend, and a sub-optimal approach to separating cars and trucks.
X U.S. Steel
$29.96

-0.29 (-0.96%)

04/30/18
BMOC
04/30/18
NO CHANGE
Target $45
BMOC
Market Perform
U.S. Steel price target lowered to $45 from 50 at BMO Capital
BMO Capital analyst David Gagliano lowered his price target on U.S. Steel to $45, saying that despite the "inexpensive" valuation of the sector amid the persisting high steel prices, the company is faced with execution risk within its 3-year "revitalization program". Gagliano keeps his Market Perform rating on U.S. Steel, adding that steel investors are typically sensitive to volatility and calling for greater visibility and execution to justify a more constructive view.
04/30/18
JPMS
04/30/18
NO CHANGE
Target $67
JPMS
Overweight
U.S. Steel shares oversold at current levels, says JPMorgan
JPMorgan analyst Michael Gambardella calls U.S. Steel "another oversold buying opportunity." The analyst thinks investors should focus on the company's "strong earnings power" in the second half of 2018 implied by its EBITDA guidance. Market conditions will continue to remain supportive for steel prices in the second half and 2019 with the President's actions on Section 232 and trade related matters, Gambardella tells investors in a research note. He lowered his price target for the shares to $67 from $69 and reiterates an Overweight rating on U.S. Steel.
04/30/18
SBSH
04/30/18
NO CHANGE
Target $42
SBSH
Buy
U.S. Steel selloff Friday a 'significant overreaction,' says Citi
Citi analyst Alexander Hacking says the 14% selloff in shares of U.S. Steel on Friday seems like a "significant overreaction" to the "poor" Q2 guidance. The analyst expects a "significant uplift in profits" in the second half of 2018 as current pricing flows through. His bull thesis on the shares is unchanged but he lowered his price target for Buy-rated U.S. Steel to $42 from $46.
04/30/18
LBOW
04/30/18
NO CHANGE
Target $49
LBOW
Buy
U.S. Steel price target lowered to $49 from $63 at Longbow
Longbow analyst Chris Olin lowered his price target on U.S. Steel to $49 from $63 due to using a more conservative multiple, though he noted that management expects much higher price realizations in the second half and he sees it being set up well for a strong performance in the back half of the year. Olin maintains a Buy rating on U.S. Steel shares.
AKS AK Steel
$4.31

-0.06 (-1.37%)

05/30/18
05/30/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Hold from Buy at Maxim with analyst Nehal Chokshi saying he sees high risk that FY19 will be a "down year" given declines in the broader smartphone market. 2. AK Steel (AKS) downgraded to Sell from Neutral at Goldman Sachs with analyst Matthew Korn citing continued underperformance by the company in terms of pricing and margins and also points to its limited visibility around downstream operations. 3. AbbVie (ABBV) downgraded to Underperform from Neutral at Credit Suisse with analyst Vamil Divan saying he is increasingly concerned about the longevity of its flagship product Humira. 4. Petrobras (PBR) downgraded to Hold from Buy at Santander. 5. Hope Bancorp (HOPE) downgraded to Neutral from Buy at DA Davidson with analyst Gary Tenner saying that while the company has posted "solid profitability metrics," its 100% loan/deposit ratio will make it challenging to fund growth without hurting net interest margins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/09/18
DBAB
07/09/18
DOWNGRADE
Target $5
DBAB
Hold
AK Steel downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded AK Steel to Hold and lowered his price target for the shares to $5 from $6. The analyst believes the steel sector is underappreciated but moderated his positive view on the Steel & Service Center space. He is "not of the view that the cycle will be sustainable" and continues to prefer mini-mills over integrated.
05/29/18
GSCO
05/29/18
DOWNGRADE
Target $4
GSCO
Sell
AK Steel downgraded to Sell at Goldman Sachs on disappointing margins, pricing
As reported earlier, Goldman Sachs analyst Matthew Korn downgraded AK Steel to Sell from Neutral and lowered his price target to $4 from $6. The analyst cites continued underperformance by the company in terms of pricing and margins and also points to its limited visibility around downstream operations. Korn adds that AK Steel carries some additional downside valuation potential relative to his other stocks in the steel sector.
07/09/18
DBAB
07/09/18
DOWNGRADE
Target $12
DBAB
Hold
Ryerson downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Ryerson to Hold and lowered his price target for the shares to $12 from $13. The analyst believes the steel sector is underappreciated but moderated his positive view on the Steel & Service Center space. He is "not of the view that the cycle will be sustainable" and continues to prefer mini-mills over integrated. Terry this morning also downgraded AK Steel (AKS) to Hold.
NUE Nucor
$63.48

0.07 (0.11%)

06/06/18
LBOW
06/06/18
NO CHANGE
Target $90
LBOW
Buy
Nucor expected to have a positive mid-quarter update, says Longbow
Longbow analyst Chris Olin is looking for a positive mid-quarter update from Nucor with positive commentary about nonresidential construction demand, wider mini-mill spreads, steady downstream margins, and investment contributions to push 2H 2018 expectations higher. Olin's expects Q2 earnings of $1.68, in-line with consensus, and sees increasing construction spending driving 2-3 years of additional long product volume growth. The analyst expects consensus estimates to move much higher, reflecting recent transaction volumes for bar, beam, and plate products and visible volume strength across all of the carbon steel mills. Olin rates Nucor a Buy with a $90 price target.
07/24/18
07/24/18
UPGRADE
Target $77

Overweight
Nucor upgraded to Overweight on broadening EPS power at KeyBanc
As previously reported, KeyBanc analyst Philip Gibbs upgraded Nucor to Overweight from Sector Weight, with a $77 price target, given better appreciation of self-help growth initiatives in Fabrication and Raw Materials. Further, the analyst notes that company-specific drivers could add 20% to his EPS power view over time.
05/18/18
SBSH
05/18/18
NO CHANGE
SBSH
Nucor and Steel Dynamics should ramp up capital returns, says Citi
Nucor (NUE) and Steel Dynamics (STLD) should consider re-visiting their aggressive capital return programs from the 2006-2008 peak, Citi analyst Alexander Hacking tells investors in a research note. The company's current cash flows are elevated and expected to remain so for the next three years, the analyst adds. Further, he believes their growth opportunities "are more limited given more inflated asset values." If each company committed to paying out 50% of discretionary operating cash flow over the next three years, Hacking estimates cash returns would total $3.1B or $9.88 per share for Nucor and $1.7B or $7.23 per share for Steel Dynamics without increasing leverage. This would still leave 45% of operating cash flow available for growth capex or acquisitions, more than sufficient to show that Section 232 profits are being reinvested, the analyst contends.
07/24/18
KEYB
07/24/18
UPGRADE
KEYB
Overweight
Nucor upgraded to Overweight from Sector Weight at KeyBanc
STLD Steel Dynamics
$43.54

-0.77 (-1.74%)

04/18/18
UBSW
04/18/18
INITIATION
Target $47
UBSW
Neutral
Steel Dynamics initiated with a Neutral at UBS
UBS analyst Andreas Bokkenheuser last night initiated Steel Dynamics with a Neutral rating and $47 price target. The analyst is cautious on the U.S. Steel sector as he believes demand is in structural decline, falling 1% per year over the past 20 years. The recent price rally was supply, not demand driven, Bokkenheuser tells investors in a research note. He believes that leading indicators now point to a mid-year price and volume reversal.
04/19/18
COWN
04/19/18
NO CHANGE
Target $60
COWN
Outperform
Steel Dynamics remains a top idea, says Cowen
Cowen analyst Novid Rassouli noted Steel Dynamics reported better than expected Q1 results. The analyst cited benefits from meaningful improvements in flat rolled operations, shipments, and the metal spread. Management remained upbeat and expect price momentum and steel consumption to continue throughout 2018, said Rassouli, who reiterates his Outperform rating and $60 price target and said Steel Dynamics remains a top idea.
06/14/18
KEYB
06/14/18
DOWNGRADE
KEYB
Sector Weight
Steel Dynamics downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Philip Gibbs downgraded Steel Dynamics to Sector Weight citing valuation.
AA Alcoa
$45.01

1.99 (4.63%)

07/24/18
DBAB
07/24/18
NO CHANGE
Target $55
DBAB
Buy
Alcoa screens as inexpensive after selloff, says Deutsche Bank
Deutsche Bank analyst Chris Terry says that following the 16% decline in the past two days after earnings, shares of Alcoa screen as inexpensive. The analyst lowered his price target to $55 from $70 to reflect the weaker than expected Q2 results. He maintains a Buy rating on Alcoa, however, with 36% upside potential.
07/23/18
MSCO
07/23/18
NO CHANGE
Target $57
MSCO
Overweight
Alcoa post-earnings selloff presents attractive entry point, says Morgan Stanley
Morgan Stanley analyst Piyush Sood remains constructive on Alcoa as he believes aluminum and alumina prices be supported by China's winter cuts, operations should improve on lower maintenance headwinds and smelter restarts and he thinks the company will initiate a dividend within about 3 months. He sees last week's roughly 20% selloff as investors reacted to the Q2 EBITDA miss and larger than expected FY18 guidance cut as an opportunity to buy shares at an attractive entry point, Sood tells investors. He lowered his price target to $57 from $60 to factor in updated guidance but maintains an Overweight rating on Alcoa shares.
07/19/18
BMOC
07/19/18
NO CHANGE
Target $75
BMOC
Outperform
Alcoa price target lowered to $75 from $80 at BMO Capital
BMO Capital analyst David Gagliano lowered his price target on Alcoa to $75 after its Q2 results, saying its adjusted EBITDA missed expectations in Q2 and the company also reduced the FY18 EBITDA guidance to reflect higher input costs. The analyst also kept his Outperform rating, noting that despite the lowered outlook, shares still trade at "only" 3.6-times his expected FY19 EBITDA on alumina/aluminum prices that are near global marginal cost. Gagliano adds that global deficit conditions in aluminum are still likely.
07/19/18
JEFF
07/19/18
NO CHANGE
Target $65
JEFF
Buy
Alcoa shares look undervalued despite guidance cut, says Jefferies
Jefferies analyst Christopher LaFemina says Alcoa's guidance cut on lower commodity prices, higher energy costs and U.S. tariffs offset the company's "solid" Q2 results. Alcoa continues to reduce its pension liability and is positioned to return cash to shareholders in the second half of 2018, LaFemina tells investors in a research note. He recommends buying the stock on the post-earnings weakness and keeps a Buy rating on Alcoa with a $65 price target. The analyst thinks the shares look undervalued at current levels.
CENX Century Aluminum
$12.15

0.01 (0.08%)

05/04/18
JPMS
05/04/18
DOWNGRADE
Target $21
JPMS
Neutral
Century Aluminum downgraded on higher alumina costs at JPMorgan
JPMorgan analyst Michael Gambardella downgraded Century Aluminum to Neutral from Overweight and lowered his price target for the shares to $21 from $29. The downgrade reflects the analyst's estimates for higher alumina costs and modestly lower Midwest premium. While Section 232 will likely result in a higher Midwest premium over the near to medium term, potential alumina shortages from the Alunorte refinery outage and the uncertainty surrounding U.S. sanctions on Russia could cause alumina prices to remain elevated for a period of time, Gambardella tells investors in a research note.
08/02/18
DBAB
08/02/18
UPGRADE
Target $20
DBAB
Buy
Century Aluminum upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Jeremy Kliewer upgraded Century Aluminum to Buy with an unchanged price target of $20. The analyst cites the company's Q2 results and upcoming production enhancements for the upgrade.
06/20/18
RILY
06/20/18
INITIATION
Target $27
RILY
Buy
Century Aluminum initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Lucas Pipes started Century Aluminum with a Buy rating and $27 price target.
06/21/18
06/21/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alcoa (AA) initiated with a Neutral at B. Riley FBR while Century Aluminum (CENX) was initiated with a Buy. 2. Westlake Chemical (WLK) initiated with an Outperform at Bernstein while Westlake Chemical Partners (WLKP) was initiated with a Market Perform. 3. RealPage (RP) initiated with an Overweight at JPMorgan. 4. JBG Smith Properties (JBGS) initiated with a Sell at Stifel. 5. Kimberly-Clark (KMB) initiated with an Underweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CLF Cleveland-Cliffs
$10.32

0.09 (0.88%)

07/23/18
07/23/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Duke Energy (DUK) upgraded to Neutral from Underweight at JPMorgan with analyst Christopher Turnure saying execution risk is priced into the shares at current levels and the company's visibility is improved following recent regulatory outcomes. 2. SunTrust (STI) upgraded to Buy from Neutral at B. Riley FBR with analyst Steve Moss citing the company's better outlook for revenue growth and efficiency improvement following its "good" Q2 results. 3. Cleveland-Cliffs (CLF) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Gambardella citing the company's "strong" U.S. iron ore earnings momentum and the removal of an overhang with the Asia Pacific Iron Ore sale. 4. Delphi Technologies (DLPH) upgraded to Outperform from Perform at Oppenheimer with analyst Noah Kaye saying that trade risks, peak U.S. SAAR concerns, light duty diesel decline and potential long-term disruption from electrification have all contributed to a tempest of negative sentiment on the auto suppliers. 5. Essex Property Trust (ESS) upgraded to Market Perform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/23/18
JPMS
07/23/18
UPGRADE
Target $15
JPMS
Overweight
Cleveland-Cliffs upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Michael Gambardella upgraded Cleveland-Cliffs to Overweight and raised his price target for the shares to $15 from $9. The analyst cites the company's "strong" U.S. iron ore earnings momentum and the removal of an overhang with the Asia Pacific Iron Ore sale. Gambardella is incrementally more positive on the shares following last week's Q2 results.
07/23/18
SBSH
07/23/18
NO CHANGE
Target $12
SBSH
Buy
Cleveland-Cliffs shares have room to move higher, says Citi
Citi analyst Daniel Knauff sees room for Cleveland-Cliffs shares to move higher following Friday's 13% post-earnings really. The analyst raised his price target for the stock to $12 from $11 and keeps a Buy rating on the name. As Cleveland-Cliffs delivers on deleveraging, begins capital returns and de-risks the HBI project the stock can appreciate further, Knauff tells investors in a research note. He keeps a Buy rating on the shares.
REGN Regeneron
$368.77

-3.55 (-0.95%)

08/06/18
RHCO
08/06/18
NO CHANGE
Target $400
RHCO
Hold
Regeneron price target raised to $400 from $344 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Regeneron to $400 after its Q2 earnings beat, with Eylea sales robust internationally and Dupixent, Praluent, and Kevzara all performing well. The analyst also keeps his Hold rating, citing competitive headwinds and pricing pressures in the long run. Suneja adds that while Regeneron's disclosure on IO and C5 assets is "intriguing", given the early stage of the assets, he remains neutral on the stock.
08/03/18
BMOC
08/03/18
NO CHANGE
Target $388
BMOC
Market Perform
Regeneron price target raised to $388 from $361 at BMO Capital
BMO Capital analyst Matthew Luchini raised his price target on Regeneron to $388 after its Q2 results showing 'in-line' Eylea sales, a beat from Dupixent, and better than expected earnings coming from lower expenses and taxes. The analyst also attributes the recent improved investor sentiment to a potential weekly SubQ C5 inhibitor, which is expected to start a Phase II trial in 2019. Longer term, the analyst keeps his Market Perform rating on Regeneron given the "concerns about VEGF competitors and key pipeline opportunity uncertainty".
08/08/18
LEER
08/08/18
NO CHANGE
LEER
Regeneron, Amgen most exposed to Medicare Part B changes, says Leerink
After the Centers for Medicare and Medicaid Services announced that Medicare Advantage plans will have the option in 2019 of applying step therapy for physician-administered and other Part B drugs for new patients, Leerink analyst Geoffrey Porges said the end goal is to create MA plan formularies that can be used as a tool to negotiate with pharmaceutical makers for lower drug prices. Among the stocks he covers, Porges identifies Regeneron (REGN) and Amgen (AMGN) as among those with the most exposure to increased competitive intensity in Part B. For Regeneron, he sees the news re-igniting speculation about the threat of biosimilars and substitution with compounded Avastin, while for Amgen the change means that preference for its growth factor products facing biosimilar competition is likely to be challenged, the analyst said. Regeneron shares are down 4.6% to $373.34 in morning trading, while Amgen is down 2.2% to $195.89.
08/08/18
PIPR
08/08/18
NO CHANGE
PIPR
Overweight
Piper says CMS Part B headlines 'scary,' but Regeneron pullback an overreaction
Piper Jaffray analyst Christopher Raymond said he would be a buyer on weakness in shares of Regeneron after CMS announced new rules giving Medicare Advantage plans the option of implementing "step therapy" to introduce competition. He checked in with leading drug pricing and reimbursement experts, whose view is that this may drive discounting and competition between Eylea and Lucentis, much like what exists today with private pay plans. After speaking with management, Raymond estimates about 3.4% of 2019 Eylea revenue is at risk. Assuming Regeneron has to price at Eylea at a 30% discount translates to a roughly $40M revenue impact and a 36c, or 1.5%, hit to EPS in 2019, said Raymond, who called the 6% pullback in the stock an overreaction in light of those estimates. He maintains an Overweight rating on Regeneron shares.
AMGN Amgen
$194.43

0.5 (0.26%)

07/30/18
PIPR
07/30/18
NO CHANGE
PIPR
Arrowhead pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said he would remain a buyer of Arrowhead Pharmaceuticals shares ahead of a "busy" second half of the year. The company could have five RNAi candidates in the clinic this year, and partner Amgen (AMGN) nominated AMG-890 as a clinical candidate that could begin clinical trials this year. Tenthoff reiterated an Overweight rating and $17 price target on Arrowhead shares.
08/07/18
STFL
08/07/18
INITIATION
Target $30
STFL
Buy
Alder Biopharmaceuticals initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.
07/27/18
JEFF
07/27/18
NO CHANGE
Target $220
JEFF
Buy
Amgen price target raised to $220 from $200 at Jefferies
Jefferies analyst Michael Yee raised his price target for Amgen to $220 saying the company last night reported "another strong quarter." He thinks Amgen shares "will go well north" of $200-$220 if the company can manage Neulasta biosimilar risk and "take the fears off the table." Yee keeps a Buy rating on the stock.
RHHBY Roche
$0.00

(0.00%)

07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
JNJ Johnson & Johnson
$130.75

-0.45 (-0.34%)

07/12/18
07/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Sell at Goldman Sachs with analyst Jami Rubin saying the stock is down 10% year-to-date and 15% from its recent all-time high of $148. 2. Hallmark Financial (HALL) upgraded to Outperform from Market Perform at Raymond James. 3. Transocean (RIG), Ensco (ESV), and Rowan Companies (RDC) were upgraded to Buy from Hold at Tudor Pickering. 4. Precision Drilling (PDS) and Nabors Industries (NBR) were upgraded to Overweight from Equal Weight at Morgan Stanley. 5. CA Technologies (CA) upgraded to Market Perform from Underperform at Wells Fargo and Bernstein. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/18
GSCO
07/12/18
UPGRADE
GSCO
Neutral
Johnson & Johnson upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $134. The shares closed yesterday down $1.11 to $126.24. The stock is down 10% year-to-date and 15% from its recent all-time high of $148, Rubin tells investors in a research note. She notes J&J is trading in line with the large cap Pharmaceuticals group at 15 times 2019 estimates. The company's non-operational earnings revisions are now better understood by investors at current share levels, Rubin contends. The analyst this morning also downgraded Perrigo (PRGO) to Sell from Neutral.
07/13/18
FBCO
07/13/18
NO CHANGE
Target $151
FBCO
Outperform
J&J verdict likely to increase attention on lawsuits, says Credit Suisse
After a Missouri jury on Thursday ordered Johnson & Johnson to pay $4.69B to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer, Credit Suisse analyst Vamil Divan said the large number of ongoing litigations are gaining the attention of investors and is not expected to slow. Given the number of cases related to both talc and mesh and the size of the potential verdicts, Divan says it is "challenging" to put reasonable ranges on what J&J's ultimate liability may end up being, though he notes that J&J has been able to overturn many of the cases and has appealed all of the unfavorable verdicts. Divan maintains an Outperform rating and $151 price target.
BA Boeing
$339.42

-4.3 (-1.25%)

07/23/18
ARGS
07/23/18
DOWNGRADE
ARGS
Hold
General Electric downgraded to Hold at Argus on disappointing Q2
As reported earlier, Argus analyst John Eade downgraded General Electric to Hold from Buy, saying that despite his expectations of a turnaround, Q2 results were a "step in the opposite direction" suggesting the company will struggle to meet its FY18 guidance. Eade also lowers his FY18 EPS forecast to 97c from $1.03, adding that GE will need to show at least two quarter of progress before he would reconsider his rating. The analyst further states that while he expects the company to look different in 2-4 years, the outlook for its its core business segments - Power and Renewable Energy - is bleak, saying he prefers other large industrials Such as Illinois Tool Works (ITW), United Technologies (UTX) and Boeing (BA) over General Electric.
07/11/18
07/11/18
UPGRADE
Target $408

Outperform
TransDigm upgraded to Outperform on reduced risks at Cowen
As previously reported, Cowen upgraded TransDigm (TDG) to Outperform from Market Perform with a $408 price target telling investors fundamental threats to TransDigm's aftermarket/M&A playbook are abating. Analyst Gautam Khanna said contract talks between TransDigm and Boeing (BA) are close to being agreed upon with no major threats to TransDigm, and concerns regarding deal economics appear to be misplaced. Further, the Department of Defense procurement rule as of July 1 may actually provide TransDigm with more pricing power versus the old policy, Khanna wrote in a note to investors. The analyst adds, the Department of Defense inquiry is also nearing completion with any fines likely to be minimal, end markets are improving, and the company has $2.3B available for M&A or dividends.
07/23/18
07/23/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. STIFEL SAYS SELL PAPA JOHN'S: Stifel analyst Chris O'Cull downgraded Papa John's (PZZA) to Sell from Hold and cut his price target for the shares to $38 from $50. The outlook for Papa John's is "growing dimmer" after recent media reports indicated a "fraternal corporate culture," O'Cull told investors. The reports reinforce the consumer perception that Papa John's is not a trusted brand, the analyst added. His recent channel checks indicate the company's domestic same-restaurant-sales are running down in the mid-teens since last week's media report about the company's founder using a racial slur. Papa John's is in a "precarious position," as it needs a "strategic savior" but is struggling to find one "willing to underwrite a transaction given the brand damage," O'Cull contended. Papa John's shares are down 7% in midday trading BTIG SAYS BUY SPOTIFY: BTIG analyst Rich Greenfield initiated Spotify (SPOT) with a Buy rating and a price target of $230, saying that awaiting a better entry on the stock price "has not worked." The analyst contended that the company will be a "long-term winner" in the subscription music category that remains in its infancy and will "grow significantly for years to come." DEUTSCHE RAISES QUALCOMM TARGET TO $60: Deutsche Bank analyst Ross Seymore raised his price target for Qualcomm (QCOM) shares to $60 from $55 after concluding that removal of the uncertainty from the NXP Semiconductors (NXPI) deal likely leads to incremental upside in either scenario. The analyst said he has no way of assigning probabilities of deal approval given the politically charged nature of the pending regulatory ruling from China's State Administration for Market Regulation. Seymore kept Hold ratings on both Qualcomm and NXP. ARGUS CUTS GE TO HOLD: Argus analyst John Eade downgraded General Electric (GE) to Hold from Buy, saying that despite his expectations of a turnaround, Q2 results were a "step in the opposite direction" suggesting the company will struggle to meet its FY18 guidance. Eade lowered his FY18 EPS forecast to 97c from $1.03, adding that GE will need to show at least two quarter of progress before he would reconsider his rating. The analyst prefers other large industrials such as Illinois Tool Works (ITW), United Technologies (UTX) and Boeing (BA) over General Electric, he added.

TODAY'S FREE FLY STORIES

MO

Altria Group

$58.61

-0.48 (-0.81%)

, BTI

British American Tobacco

$35.55

-0.96 (-2.63%)

11:22
11/15/18
11/15
11:22
11/15/18
11:22
Hot Stocks
CVS 'applauds' FDA announcement to restrict flavored tobacco products »

CVS Health (CVS)…

MO

Altria Group

$58.61

-0.48 (-0.81%)

BTI

British American Tobacco

$35.55

-0.96 (-2.63%)

PM

Philip Morris

$85.26

-0.25 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:20
11/15/18
11/15
11:20
11/15/18
11:20
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/15/18
11/15
11:17
11/15/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/15/18
11/15
11:16
11/15/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$34.69

0.46 (1.34%)

, QRVO

Qorvo

$63.65

0.77 (1.22%)

11:15
11/15/18
11/15
11:15
11/15/18
11:15
OnTheFly
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's top…

MYL

Mylan

$34.69

0.46 (1.34%)

QRVO

Qorvo

$63.65

0.77 (1.22%)

LITE

Lumentum

$39.14

0.29 (0.75%)

AAPL

Apple

$188.37

1.56 (0.84%)

ATNX

Athenex

$10.80

0.52 (5.06%)

PCG

PG&E

$19.54

-6.12 (-23.85%)

HZNP

Horizon Pharma

$20.53

-0.7 (-3.30%)

PYPL

PayPal

$84.29

0.24 (0.29%)

WP

Worldpay

$82.00

-0.71 (-0.86%)

FDC

First Data

$18.00

0.17 (0.95%)

SQ

Square

$70.75

0.9 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 27

    Nov

  • 12

    Dec

  • 18

    Dec

  • 18

    Dec

  • 03

    Mar

MTOR

Meritor

$15.36

-1.95 (-11.27%)

11:12
11/15/18
11/15
11:12
11/15/18
11:12
Recommendations
Meritor analyst commentary  »

Meritor earnings report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Dec

AAPL

Apple

$188.71

1.9 (1.02%)

, LITE

Lumentum

$39.27

0.42 (1.08%)

11:12
11/15/18
11/15
11:12
11/15/18
11:12
OnTheFly
Morgan Stanley says buy Apple on any weakness amid supply chain ‘noise’ »

Calling the recent…

AAPL

Apple

$188.71

1.9 (1.02%)

LITE

Lumentum

$39.27

0.42 (1.08%)

QRVO

Qorvo

$63.84

0.96 (1.53%)

GLW

Corning

$31.59

0.18 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

KBH

KB Home

$17.07

-3.73 (-17.93%)

11:10
11/15/18
11/15
11:10
11/15/18
11:10
Options
KB Home puts lead calls 4:1 and implied volatility spikes to 52-week highs »

KB Home puts lead calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:01
11/15/18
11/15
11:01
11/15/18
11:01
General news
Crude inventories for week of November 9 »

Crude oil inventories…

AUY

Yamana Gold

$2.14

0.015 (0.71%)

11:00
11/15/18
11/15
11:00
11/15/18
11:00
Options
Volatility play in Yamana Gold »

Volatility play in Yamana…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSN

Celsion

$1.99

-0.08 (-3.86%)

10:55
11/15/18
11/15
10:55
11/15/18
10:55
Conference/Events
Celsion to hold a conference call »

Conference Call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

AWI

Armstrong World

$64.99

-1.01 (-1.53%)

10:55
11/15/18
11/15
10:55
11/15/18
10:55
Conference/Events
Armstrong World to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

FOXA

21st Century Fox

$47.66

-0.27 (-0.56%)

10:52
11/15/18
11/15
10:52
11/15/18
10:52
Hot Stocks
FOX Sports, Major League Baseball reach new multi-year agreement »

FOX Sports and Major…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$31.89

-1.32 (-3.97%)

10:50
11/15/18
11/15
10:50
11/15/18
10:50
Options
Second day of big option prints in Macy's »

Second day of big option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$99.47

-2.11 (-2.08%)

10:49
11/15/18
11/15
10:49
11/15/18
10:49
Periodicals
Sanders bill would prevent stock buybacks unless companies pay $15/hr, CNBC says »

Senator Bernie Sanders is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

GPRE

Green Plains

$16.94

-0.23 (-1.34%)

, GPP

Green Plains Partners

$14.68

(0.00%)

10:46
11/15/18
11/15
10:46
11/15/18
10:46
Hot Stocks
Green Plains announces permanent closure of Hopewell, VA ethanol facility »

Green Plains (GPRE)…

GPRE

Green Plains

$16.94

-0.23 (-1.34%)

GPP

Green Plains Partners

$14.68

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
11/15/18
11/15
10:45
11/15/18
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
11/15/18
11/15
10:45
11/15/18
10:45
General news
Breaking General news story  »

Federal Reserve Chairman…

10:45
11/15/18
11/15
10:45
11/15/18
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

10:45
11/15/18
11/15
10:45
11/15/18
10:45
General news
Breaking General news story  »

Week of 11/9 EIA…

FCE.A

Forest City

$25.25

(0.00%)

, BAM

Brookfield

$43.56

-0.27 (-0.62%)

10:44
11/15/18
11/15
10:44
11/15/18
10:44
Hot Stocks
Forest City stockholders approve acquisition by Brookfield fund »

Forest City Realty Trust…

FCE.A

Forest City

$25.25

(0.00%)

BAM

Brookfield

$43.56

-0.27 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

10:40
11/15/18
11/15
10:40
11/15/18
10:40
Options
Whale of a trade in Invesco Senior Loan ETF »

Whale of a trade in…

10:35
11/15/18
11/15
10:35
11/15/18
10:35
General news
Treasury Option Action: a flurry of call positioning »

Treasury Option Action: a…

DCPH

Deciphera

$22.50

1.88 (9.12%)

, BPMC

Blueprint Medicines

$54.16

-2.22 (-3.94%)

10:32
11/15/18
11/15
10:32
11/15/18
10:32
Recommendations
Deciphera, Blueprint Medicines analyst commentary  »

Deciphera remains well…

DCPH

Deciphera

$22.50

1.88 (9.12%)

BPMC

Blueprint Medicines

$54.16

-2.22 (-3.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

10:30
11/15/18
11/15
10:30
11/15/18
10:30
General news
EIA natural gas storage change for week ending November 9 »

Gas inventories 39 Bcf…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.